147 related articles for article (PubMed ID: 8192471)
21. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
22. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
Klepser ME; Wolfe EJ; Pfaller MA
J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro activity of amphotericin B by time-kill curve methodology against large and small capsulate C. neoformans isolates.
Córdoba S; Afeltra J; Vitale RG
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):260-2. PubMed ID: 21917396
[TBL] [Abstract][Full Text] [Related]
24. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques.
Moraes EM; Prímola NS; Hamdan JS
Mycoses; 2003 Jun; 46(5-6):164-8. PubMed ID: 12801356
[TBL] [Abstract][Full Text] [Related]
25. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
Li M; Liao Y; Chen M; Pan W; Weng L
Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
[TBL] [Abstract][Full Text] [Related]
27. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
Franzot SP; Hamdan JS
Antimicrob Agents Chemother; 1996 Mar; 40(3):822-4. PubMed ID: 8851624
[TBL] [Abstract][Full Text] [Related]
29. In vitro susceptibility of Cryptococcus neoformans serotypes to GM 237354 derivative of the sordarin class.
Torres-Rodríguez JM; Morera Y; Baró T; López O; Alía C; Jiménez T
Mycoses; 2002 Oct; 45(8):313-6. PubMed ID: 12572721
[TBL] [Abstract][Full Text] [Related]
30. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.
Johnson EM; Ojwang JO; Szekely A; Wallace TL; Warnock DW
Antimicrob Agents Chemother; 1998 Jun; 42(6):1412-6. PubMed ID: 9624486
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
32. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
Rossato L; Loreto ÉS; Zanette RA; Chassot F; Santurio JM; Alves SH
Folia Microbiol (Praha); 2016 Sep; 61(5):399-403. PubMed ID: 26847460
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans.
Maxwell MJ; Messer SA; Hollis RJ; Diekema DJ; Pfaller MA
J Clin Microbiol; 2003 Jan; 41(1):97-9. PubMed ID: 12517832
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
[TBL] [Abstract][Full Text] [Related]
36. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
37. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
38. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
39. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro.
Alcouloumre MS; Ghannoum MA; Ibrahim AS; Selsted ME; Edwards JE
Antimicrob Agents Chemother; 1993 Dec; 37(12):2628-32. PubMed ID: 8109927
[TBL] [Abstract][Full Text] [Related]
40. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Sar B; Monchy D; Vann M; Keo C; Sarthou JL; Buisson Y
J Antimicrob Chemother; 2004 Aug; 54(2):563-5. PubMed ID: 15254027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
